FDA Approves Icotyde (Icotrokinra), an Oral Peptide, for Plaque Psoriasis

The FDA has approved Icotyde (icotrokinra) to treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy. The approval, dated March 17, 2026, is listed on the FDA Novel Drug Approvals for 2026 page.

Icotrokinra is an oral peptide that targets the IL-23 receptor. Its developers described it as the first oral peptide of its kind for this use, a notable point in a field where peptide products have historically faced oral delivery challenges.

Only the labeled indication stated above is reported here, as a regulatory fact drawn from the FDA approvals list. No claim beyond that labeled population and condition is made in this post.

As with every FDA approval, the decision applies to the specific product, Icotyde, and the specific indication on its label. It does not extend to compounded formulations, research compounds, or any other use of the molecule.